Condition
Functional Gastrointestinal Disorders
Functional gastrointestinal disorders are conditions in which the gut doesn't work as it should even though no structural damage shows up, with irritable bowel syndrome the best known, alongside functional dyspepsia, constipation and bloating. Probiotics and enteric-coated peppermint oil are the supplements with the strongest evidence, but little research on their specific findings has been reviewed here so far. Because effects of probiotics vary by strain, and other options like psyllium, ginger and artichoke leaf have only moderate evidence, it's still early to say what works best.
- Supplements studied
- 1
- Graded outcomes
- 0
- People studied
- 702
Evidence by supplement
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Abdominal Pain | Improves (the measure goes down) | 1 study | 481 people | |||
Studies that measured abdominal pain | ||||||
The Functional Gastrointestinal Disorders (FGIDs) Support protocol
2 primary supplements · 7 supporting supplements
- Probiotics10–50 billion CFU daily (strains like B. infantis 35,624, L. plantarum 299v)
- Peppermint Oil (Enteric-Coated)180–225 mg enteric-coated capsules 2–3 times daily
Shop the evidence-backed picks
The collection holds the supplements we grade A or B for its theme, in third-party tested products where the catalog has them. It opens in our Fullscript store. You can look through it without signing in; Fullscript asks for a free account to order.
We earn from purchases made in our Fullscript store, and links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Full disclosure
Studies cited
30 studies from PubMed
- Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial
- Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
- Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
- Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial
- Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus
- Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review.
- Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis
- Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial
- Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial
- Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial
- Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study
- 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938
- Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial
- Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study
- Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial
- Salivary IgA response to probiotic bacteria and mutans streptococci after the use of chewing gum containing Lactobacillus reuteri
- Lactobacillus reuteri ATCC55730 in cystic fibrosis
- A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults
- No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy
- Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study
- Lactobacillus reuteri compared with placebo as an adjuvant in Helicobacter pylori eradication therapy: a meta-analysis of randomized controlled trials.
- Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study
- Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans
- The efficacy and acceptability of Lactobacillus reuteri for the treatment of depression: A systematic review and meta-analysis.
- Probiotics for treating acute infectious diarrhoea.
- The influence of probiotics on gastrointestinal tract infections among children attending childcare: A systematic review and meta-analysis
- A systematic review and meta-analysis: the therapeutic and preventive effect of Lactobacillus reuteri DSM 17,938 addition in children with diarrhea.
- Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis
- Limosilactobacillus reuteri consumption significantly reduces the total cholesterol concentration without affecting other cardiovascular disease risk factors in adults: A systematic review and meta-analysis.
- Adjunctive benefit of probiotic supplementation along with nonsurgical therapy for peri-implant diseases - A systematic review and meta-analysis.